A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis.

A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis. Oncotarget. 2018 Jan 23;9(6):7182-7196 Authors: Kidd M, Modlin IM, Drozdov I, Aslanian H, Bodei L, Matar S, Chung KM Abstract No effective blood biomarker exists to detect and clinically manage bronchopulmonary (BP) neuroendocrine tumors (NET). We developed a blood-based 51 NET-specific transcript set for diagnosis and monitoring and evaluated clinical performance metrics. It accurately diagnosed the tumor and differentiated stable from progressive disease as determined by RECIST criteria. Gene expression was evaluated in: a) publicly available BPNET transcriptomes (GSE35679); b) two BPNET cell-lines; and c) BPNET tissue with paired blood (n = 7). Blood gene expression was assessed in 194 samples including controls, benign lung diseases, malignant lung diseases and small bowel NETs. A separate validation study in 25 age- and gender-matched BPNETs/controls was performed. Gene expression measured by real-time PCR was scored (0-100%; normal: < 14%). Regression analyses, Principal Component Analysis (PCA), hierarchical clustering, Fisher's and non-parametric evaluations were undertaken. All 51 genes were identified in BPNET transcriptomes, tumor samples and cell-lines. Significant correlations were evident between paired tumor and blood (R2:0.63-0.91, p < 0.001). PCA and hierarchical clustering identified blood gene expression was significantly different between lung ca...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research